TEAE

[키워드] abstracts accelerate acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-CD147 antibody assigned biodistribution study blocking C max cardiac blood–pool ratio CD147 Cohort cohorts conducted control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients COVID-19 pneumonia determine discharged dosage double-blinded Efficacy eight enrolled evaluate Evidence exploratory phase 2 exploratory phase 2 study healthy subjects healthy volunteer healthy volunteers hospitalized patient humanized IgG in vitro incidence indicated Infection involved lung lung tissue Meplazumab meplazumab treatment monoclonal antibody Patient patients Peripheral blood pharmacokinetic characteristics pharmacokinetics Phase 1 phase 1 study phase 1 trial Phase 2 Placebo placebo-controlled Pneumonia positive Prevent Randomized reached recent receptor reduced respiratory Safety safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication serum severe acute respiratory syndrome Coronavirus severity significantly subject suppress TEAE titer Tolerability Tolerance treatment-emergent adverse event Trial virus
[DOI] 10.1038/s41392-021-00603-6 PMC 바로가기 [Article Type] Clinical Trial